Rasagiline improves quality of life in patients with early Parkinson's disease
- Kevin M. Biglan(corresponding author),
- Steven Schwid,
- Shirley Eberly,
- Karen Blindauer,
- Stanley Fahn,
- Tamar Goren
- Johns Hopkins University,
- University of Rochester,
- Medical College of Wisconsin,
- Teva Pharmaceutical Industries Ltd.,
- University of Pennsylvania,
- Columbia University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewAbstract
<p>The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early PD. Patients with early untreated PD were randomly assigned to once-daily rasagiline 1 mg/day, rasagiline 2 mg/day, or placebo in a 6-month, double-blind trial (n = 404). At the end of 6 months, patients entered the preplanned, active-treatment phase in which those receiving 1 mg/day and 2 mg/day of rasagiline continued on their previously assigned dosages and those receiving placebo switched to rasagiline 2 mg/day, while maintaining blinding to treatment assignments. QOL was measured with the Parkinson's Disease Quality of Life questionnaire (PDQUALIF) at 0, 14, 26, and 52 weeks after randomization. Analysis of the change in PDQUALIF scores from baseline to 6 months showed adjusted treatment effects (with 95% confidence interval) favoring rasagiline over placebo of -2.91 units (-5.19, -0.64, P = 0.01) for the 1 mg/day group and -2.74 units (-5.02, -0.45, P = 0.02) for the 2 mg/day. Subscore analysis attributed most of this benefit to the self-image/sexuality domain. At 12 months (n = 266), with all groups receiving rasagiline for at least 6 months, no significant differences in PDQUALIF scores were seen between groups. Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 616-623 (8 pages)Journal (Volume, Issue Number)
Movement Disorders (Volume 21, Issue 5)Publication milestones
- Published - 05/2006
Publication status
Published - 05/2006
ISSN
0885-3185Publication IDs
- Scopus: 33744915026
- PubMed: 16450340
Publication metrics
Metrics
SciVal
FWCI
2.75
SciVal
Author count
89
SciVal
citations
59
SciVal
Paper percentile
90
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.01
Fractional count
88
Fractional count
0.99
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
65
Citation count
71
